Court rules in favor of Novartis over Glivec price

Published: 2010-01-26 07:00:00

Updated: 2010-01-26 07:00:00

A Seoul court said on January 22 that it has ruled in favor of Novartis AG, the Swiss drug giant, who sought to overturn an earlier government decision to reduce the price of Glivec (imatinib mysylate) by 14 percent.

The Seoul Administrative Court reversed the health ministry's decision last S...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK